GLP-1 medications are transforming the treatment of obesity, diabetes, and cardiometabolic disease, but they are also becoming one of the fastest-growing drivers of healthcare spend. For employers and plan sponsors, the challenge is balancing appropriate access, sustainable outcomes, and long-term affordability. In this white paper, learn how leading organizations are approaching metabolic health through integrated pharmacy, medical, behavioral, and clinical strategies that support both member outcomes and financial sustainability. Key topics include: The financial impact of rising GLP-1 utilization Key drivers of pharmacy spend and benefit design decisions Why behavioral and clinical support are critical to long-term success Strategies to improve adherence and reduce avoidable costs How coordinated care models can enhance cardiometabolic outcomes Download the white paper to explore a framework for managing the growing demand for GLP-1 therapies while supporting healthier populations and more sustainable benefit plans.
